Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) SHH

Currency In CNY

AD

Valuation

Market Cap10.29B
Enterprise Value10.4B
P/E Ratio-495.06
PEG Ratio3.52
Price/Sales Ratio16.04
Price/Book Ratio14.01
Enterprise/Revenue16.42
Enterprise/EBITDA136.88

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin-0.03
Operating Margin0.1
AD

Management Effectiveness

Return On Assets-0.01
Return On Equity-0.03

Income Statement

Revenue704.16M
Revenue/Share1.87
Gross Profit704.16M
EBITDA59.85M
Net Income22.23M
Diluted EPS0.05

Balance Sheet

Total Cash235.28M
Total Cash/Share0.58
Total Debt524.1M
Total Debt/Equity0.6
Current Ratio1.29
Book Value Per Share2.25

Price History

52-Week Change-9.41
52-Week High44.9
52-Week Low20.41
Moving Average 50 Days32.26
Moving Average 200 Days29.62

Statistics

Average Volume12.32M
Shares Outstanding405.41M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio-0.35
Last Split FactorN/A
Last Split DateN/A
AD